Iambic Therapeutics Announces Initial Public Offering

Iambic Therapeutics announced its initial public offering of common stock. The company is applying to list its common stock on the Nasdaq Global Select Market under the symbol 'Iam'. J.P. Morgan, Jefferies, Bofa Securities, and Citigroup are acting as underwriters for the IPO. NVIDIA Corporation beneficially owned 9.6 million shares of Iambic Therapeutics prior to the offering.